Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC

被引：0

作者：

Thongprasert, S. ^{[1
,2
]}

Geater, S. L. ^{[3
]}

Clement, D. ^{[4
]}

Abdelaziz, A. ^{[5
]}

Reyes-Igama, J. ^{[6
]}

Jovanovic, D. ^{[7
]}

Alexandru, A. ^{[8
]}

Schenker, M. ^{[9
]}

Sriuranpong, V. ^{[10
,11
]}

Serwatowski, P. ^{[12
]}

Suresh, S. ^{[13
]}

Cseh, A. ^{[14
]}

Gaafar, R. ^{[15
]}

机构：

[1] Wattanosoth Hosp, Med Oncol Unit, Chiang Mai, Thailand

[2] Bangkok Hosp Chiang Mai BDMS, Chiang Mai, Thailand

[3] Prince Songkla Univ, Songklanagarind Hosp, Dept Internal Med, Hat Yai, Thailand

[4] Reg Oncol Inst Iasi, Dept Med Oncol, Iasi, Romania

[5] Alexandria Univ, Alexandria Clin Res Ctr, Dept Clin Oncol, Alexandria, Egypt

[6] Baguio Gen Hosp & Med Ctr, Dept Internal Med Hematol & Oncol, Baguio, Philippines

[7] Clin Ctr Serbia, Clin Pulmonol, Belgrade, Serbia

[8] Oncol Inst Bucharest, Med Oncol Dept 2, Bucharest, Romania

[9] Sf Nectarie Ltd, Dept Oncol, Ctr Oncol, Craiova, Romania

[10] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok, Thailand

[11] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[12] Specialist Hosp, Dept Clin Oncol & Chemotherapy, Szczecin, Poland

[13] Boehringer Ingelheim Pharmaceut Inc, Dept Oncol, Singapore, Singapore

[14] Boehringer Ingelheim RCV GmbH & Co KG, Dept Oncol, Vienna, Austria

[15] Natl Canc Inst, Dept Med Oncol, Cairo, Egypt

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

474P

引用

页码：146 / 146

页数：1